Genfit S.A. (EPA:GNFT)
France · Delayed Price · Currency is EUR 13.02
-0.68 (-4.96%)
Sep 11, 2026, 5:36 PM CET
Genfit Employees
Genfit had 161 employees as of December 31, 2025. The number of employees decreased by 19 or -10.56% compared to the previous year.
Employees
161
Change (1Y)
-19
Growth (1Y)
-10.56%
Revenue / Employee
€440,031
Profits / Employee
€533,963
Market Cap
651.32M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 161 | -19 | -10.56% |
| Dec 31, 2024 | 180 | 21 | 13.21% |
| Dec 31, 2023 | 159 | 11 | 7.43% |
| Dec 31, 2022 | 148 | 26 | 21.31% |
| Dec 31, 2021 | 122 | -8 | -6.15% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 620 |
| Cellectis | 229 |
| DBV Technologies | 170 |
| Innate Pharma | 164 |
| Transgene | 145 |
| MedinCell | 141 |
| Nanobiotix | 100 |
| Inventiva | 77 |
Genfit News
- 3 days ago - Genfit Transcript: KOL event - Transcripts
- 3 days ago - Genfit Press release: KOL event - Filings
- 3 days ago - Genfit Slides: KOL event - Filings
- 11 days ago - Genfit Slides: Corporate presentation - Filings
- 2 months ago - GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma - GlobeNewsWire
- 2 months ago - GENFIT: June 15, 2026 Combined Shareholders Meeting Results - GlobeNewsWire
- 3 months ago - GENFIT: NASHnext®, Powered by GENFIT's Non-invasive Diagnostic Technology NIS4®, Launched via Labcorp's OnDemand Offering for Identification of At-Risk MASH - GlobeNewsWire
- 3 months ago - Genfit Earnings release: Q1 2026 - Filings